Valuation: ConvaTec Group

Market Cap 5.59B 4.89B 4.51B 4.18B 7.93B 534B 8.06B 54.05B 21.19B 262B 21B 20.55B 908B P/E 2026 *
20.3x
P/E 2027 * 15.9x
Enterprise Value 6.79B 5.94B 5.48B 5.07B 9.63B 649B 9.79B 65.64B 25.73B 318B 25.51B 24.95B 1,103B EV / Sales 2026 *
2.65x
EV / Sales 2027 * 2.42x
Free-Float
95.19%
Yield 2026 *
2.74%
Yield 2027 * 3.07%
Manager TitleAgeSince
Chief Executive Officer 62 04/08/2025
Director of Finance/CFO 51 04/08/2025
Chief Operating Officer - 01/06/2026
Director TitleAgeSince
Director/Board Member 61 01/02/2022
Chairman 78 30/09/2019
Director/Board Member 71 14/08/2017
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 5.59B
-1.10%-1.39%-29.38%-12.10% 166B
+0.13%-1.45%-7.88%-5.16% 105B
-2.80%+1.49%+0.25%+56.05% 60.23B
+3.64%-4.34%+45.42%+51.88% 49.17B
-0.15%-4.97%-14.40%-41.68% 41.49B
+0.86%-5.86% - - 34.08B
-3.16%+0.05%-16.01%-45.43% 28.58B
+0.85%-2.58%+57.54%-5.56% 24.99B
-2.15%+3.29%-9.38%+3.10% 20.64B
Average -0.38%+1.56%+3.27%+0.14% 58.88B
Weighted average by Cap. -0.46%+2.11%-6.58%+0.56%

Financials

2026 *2027 *
Net sales 2.57B 2.24B 2.07B 1.92B 3.64B 245B 3.7B 24.79B 9.72B 120B 9.63B 9.43B 417B 2.74B 2.39B 2.21B 2.04B 3.88B 261B 3.94B 26.45B 10.37B 128B 10.28B 10.05B 444B
Net income 276M 242M 223M 206M 391M 26.38B 398M 2.67B 1.05B 12.95B 1.04B 1.01B 44.86B 359M 314M 289M 268M 508M 34.23B 516M 3.46B 1.36B 16.81B 1.35B 1.32B 58.22B
Net Debt 1.2B 1.05B 968M 895M 1.7B 115B 1.73B 11.59B 4.54B 56.23B 4.5B 4.41B 195B 1.03B 905M 834M 772M 1.47B 98.73B 1.49B 9.99B 3.92B 48.48B 3.88B 3.8B 168B
Logo ConvaTec Group
ConvaTec Group Plc specializes in the development, manufacturing and marketing of medical devices and products for ostomy care, wound care, and incontinence. The group also offers perfusion devices. Net sales break down by area of activity as follows: - wound care (30.9%): antimicrobial dressings, occlusive dressings, compression bandages, etc.; - ostomy care (27.7%): skin barriers, one-piece bags, 2-piece appliance bags, urostomy bags, etc.; - incontinence care (22%); - infusion (19.4%). At the end of 2025, the group operated 7 production sites worldwide. Net sales are distributed geographically as follows: Europe (29.6%), North Americas (55.7%) and other (14.7%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA